SEC Form 4 · accession 0000899243-17-004098
Larimar Therapeutics, Inc. · LRMR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Cameron Geoffrey McDonough
Director
Period of report
Feb 13, 2017
Accepted (ET)
Feb 14, 2017 · 8:12 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001374690
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $4.18 | Feb 13, 2017 | A | 13,718 | A | — | Feb 13, 2027 | Common Stock | 13,718 | 13,718 | D |
Explanation of responses
- F1The stock option was issued in lieu of cash fees under the Non-Employee Director Compensation Policy pursuant to a Non-Qualified Stock Option Agreement and shall vest over a period of one year starting January 1, 2017 on a quarterly basis in arrears.